The first human trials of a potential Ebola vaccine could begin in the Oxford as early as mid-September.
The candidate vaccine has been being developed by the US National Institutes of Health and pharmaceutical giant GlaxoSmithKline. Funding from a consortium of British bodies has allowed the UK trials to be fast-tracked.
Professor Adrian Hill, who will be running the trials at Oxford University, said he was looking for 60 healthy individuals aged 18 to 50 to take part in the study. Volunteers will have to make nine visits over six months and will receive modest compensation for their time.
Unlike with vaccines for some other illnesses, it does not contain any infectious virus material, so it "cannot cause a person who is vaccinated to become infected with Ebola," GlaxoSmithKline said in a statement.
Manufacturers are planning to produce around 10,000 doses of the potential vaccine that will be distributed to "high-risk communities" if the trials prove successful. Other trials are being planned in the US, Gambia and Mali.
UK trials of a vaccine for the Ebola virus began today - but some experts complain that the response has been a long time coming.
A Swansea doctor who took leave to treat Ebola patients in Africa, is back on the wards after three weeks in isolation.
The first British case of Ebola in the outbreak in West Africa has been confirmed. So how would repatriation work are what are the risks?